BWX Technologies, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $350M normalized FCF base (FY26 guidance midpoint); 13% annual FCF growth years 1-5 (consistent with management 2030 revenue target of $5.5-6B); 6% growth years 6-10; 8.5% discount rate; 3% terminal growth; $1,412M net debt; 91.62M shares outstanding.

Reasoning: BWXT has highly contracted, government-backed naval nuclear and DOE revenue plus a fast-growing commercial nuclear/medical-isotope and SMR optionality segment, making a staged FCF DCF (high growth tapering to a mature rate) the most appropriate method; the discount rate reflects its low-risk government revenue base blended with higher-risk growth initiatives.